Peppermint Water BP 1973
Marketing Authorization Holder: Macarthys Laboratories Limited T/A Martindale Pharma Bampton Road Harold Hill Romford Essex RM3 8UG
General Sales List
Not classified
THR 01883/0014
Summary of Product Characteristics
Detailed prescribing information and pharmaceutical guidance from the UK Electronic Medicines Compendium.
Composition
Active and inactive ingredients
Each 5ml of oral solution contains 2.5 microlitres of Peppermint oil (*Mentha* x *piperita* L.) Excipients: Each 5 ml of oral solution contains 10 mg Nipasept Sodium, comprising; sodium methyl, ethyl and propyl parahydroxybenzoates. For a full list of excipients, see section 6.1
Pharmaceutical Form
Dosage form and administration route
Oral Solution Clear and colourless
Clinical Particulars
Therapeutic indications and usage
4.1 Therapeutic indications A traditional herbal medicinal product used for the symptomatic relief of minor digestive complaints such as dyspepsia, flatulence and stomach cramps, based on traditional use only.4.2 Posology and method of administration Adults, the elderly and children over 12 years of age: Two - eight 5 ml spoonfuls to be taken 3-4 times daily, as required This product is not recommended for use in children aged 12 years and under (see 'Section 4.4. Special warnings and precautions for use') If symptoms worsen, or persist for more than 2 weeks, a doctor or qualified healthcare practitioner should be consulted.4.3 Contraindications Hypersensitivity to Peppermint Oil preparations, menthol or any of the excipients. Obstructions of bile ducts, cholangitis, gallstones, and any other biliary diseases.4.4 Special warnings and precautions for use Do not exceed the stated dose Patients who already suffer from gastroesophageal reflux (heartburn) or hiatal hernia sometimes have an exacerbation of this symptom after taking peppermint oil. Treatment should be discontinued in these patients. Peppermint oil should be used with caution with inflamed and ulcerated conditions of the gastrointestinal tract. This product contains sodium methyl, ethyl, propyl parahydroxybenzoates [E219, E215 and E217] and should not be used by patients who are allergic to hydroxybenzoates. Allergic reactions may be delayed in onset. The use in children under 12 years is not recommended as data is not sufficient and medical advice should be sought. If symptoms worsen, or persist for more than 2 weeks a doctor or a qualified health care practitioner should be consulted.4.5 Interaction with other medicinal products and other forms of interaction None reported.4.6 Fertility, pregnancy and lactation In the absence of sufficient data, the use during pregnancy and lactation is not recommended. No studies on the effects on fertility have been performed.4.7 Effects on ability to drive and use machines No studies on the effect on the ability to drive and use machines have been performed.4.8 Undesirable effects Contact sensitivity to menthol and peppermint oil in patients presenting with intra-oral symptoms in association with burning mouth syndrome, recurrent oral ulceration or a lichenoid reaction have been reported. The frequency is not known. Allergic reactions to menthol have been reported, with headache, bradycardia, muscle tremor, ataxia, anaphylactic shock and erythematous skin rash. The frequency is not known. If these or other adverse reactions not mentioned above occur, treatment should be discontinued and a doctor or a qualified healthcare professional consulted. **Reporting of suspected adverse reactions** Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme website www.mhra.gov.uk/yellowcard.4.9 Overdose No case of overdose has been reported with this product. In the event of an overdose, treatment should be supportive and symptomatic.
Pharmacological Properties
Pharmacodynamics and pharmacokinetics
5.1 Pharmacodynamic properties Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.5.2 Pharmacokinetic properties Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.5.3 Preclinical safety data Peppermint oil was negative in two validated tests of genotoxicity, the Ames test and the mouse lymphoma assay. Weak and inconsistent genotoxic responses in other non-validated tests are probably toxicologically inconsequential. There is more evidence for genotoxicity potential of menthol and there seems to be a discrepancy between peppermint oil and its most important constituent menthol. However, the present evidence points to a very weak or totally absent genotoxicity of peppermint oil.
Pharmaceutical Particulars
Storage and handling information
6.1 List of excipients Glycerol Nipasept Sodium, (sodium methyl, ethyl and propyl parahydroxybenzoates [E219,E215 and E217]) Carbomer Citric Acid, anhydrous Purified Water6.2 Incompatibilities Not applicable6.3 Shelf life 2 years6.4 Special precautions for storage There are no special storage precautions for this product. Store in the original packaging6.5 Nature and contents of container 100 ml Amber Type III glass bottle with polypropylene screw cap with LDPE liner.6.6 Special precautions for disposal and other handling No special requirements